U. Krämer
University of Giessen
4 Papers
U. Krämer is an academic researcher from University of Giessen. The author has contributed to research in topics: Cardiomyopathy & Heart transplantation. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Heart transplantation in children and infants: short-term outcome and long-term follow-up.
Juergen Bauer,Josef Thul,U. Krämer,K. J. Hagel,Hakan Akintürk,Klaus Valeske,Ehrenfried Schindler,R. M. Bohle,Dietmar Schranz +8 more
TL;DR: It is concluded that heart transplantation in infants and children can be performed with good early and late results, and quality of life is excellent in most patients.
40
Cardiac troponin I: A marker of acute heart rejection in infant and child heart recipients?
TL;DR: Serum cardiac troponin I (cTNI) levels were retrospectively analysed in 25 heart transplant patients and demonstrate that cTNI is a not a sensitive but a specific marker of ACR in children.
16
Op-eujc220359 1..9
T. D. By,M. Schwaiger,H. Hussain,Antonio Amodeo,Thomas Martens,Ad J.J.C. Bogers,Kevin Damman,Can Gollmann-Tepeköylü,Michal Hulman,Attilio Iacovoni,U. Krämer,Antonio Loforte,Carlo Pace Napoleone,Ivan Netuka,Mustafa Özbaranp,Luz Polo,Yuri Pyar,Faiz Ramjankhans,Eugen Sandica,Joanna Śliwka,Brigitte Stiller,Alexander Kadner,Alessio Franceschini,Timothy Thiruchelvam,Daniel Zimpfer,Bart Meyns,Felix Berger,Oliver Miera +27 more
TL;DR: A focus on specific subgroups showed that survival was less in patients of younger age and lower weight as well as adverse events including neurological dysfunction, device malfunction, major infection and bleeding, which shows no significant difference from the early and later eras.
The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): third Paediatric (Paedi-EUROMACS) report.
Theo M M H de By,M. Schwaiger,H. Hussain,Antonio Amodeo,Thomas Martens,Ad J.J.C. Bogers,Kevin Damman,Can Gollmnan-Tepeköylü,Michal Hulman,Attilio Iacovoni,U. Krämer,Antonio Loforte,Carlo Pace Napoleone,Petr Němec,Ivan Netuka,Mustafa Özbaran,Luz Polo,Yuriy Pya,Faiz Ramjankhan,Eugen Sandica,Joanna Śliwka,Brigitte Stiller,Alexander Kadner,Alessio Franceschini,Timothy Thiruchelvam,Daniel Zimpfer,Bart Meyns,Felix Berger,Oliver Miera +28 more
TL;DR: The overall survival rate was 79.2% at 12 months following ventricular assist device implant and a focus on subgroups showed that survival was less in patients of younger age and lower weight, as well as adverse events including neurological dysfunction, device malfunction, major infection and bleeding.